Related Experiment Video

Updated: Jun 17, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate

Ning Zhang1, Yi Huan, Hui Huang

  • 1Institute of Materia Medica, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.

Acta Pharmacologica Sinica
|December 22, 2009
PubMed
Abstract

Insights

Atorvastatin improved insulin sensitivity and glucose tolerance in obese mice by reducing inflammation. This suggests potential for treating insulin resistance, type 2 diabetes, and cardiovascular disease.

Area of Science:

  • Metabolic research
  • Pharmacology
  • Inflammation studies

Background:

  • Insulin resistance and obesity are linked to metabolic dysfunction.
  • Chronic inflammation plays a role in insulin resistance.
  • Atorvastatin is a statin medication primarily used for lowering cholesterol.

Purpose of the Study:

  • To investigate the mechanisms by which atorvastatin affects glucose and lipid metabolism.
  • To evaluate the anti-inflammatory effects of atorvastatin in a model of insulin resistance.

Main Methods:

  • Utilized monosodium glutamate (MSG)-induced obese and insulin-resistant mice.
  • Administered atorvastatin (80 mg.kg(-1).d(-1)) or vehicle control for 30 days.
  • Assessed metabolic parameters, inflammatory markers (IL-6, TNF-alpha), and related signaling pathways (NF-kappaB, IkappaB).

Main Results:

  • Atorvastatin treatment improved insulin sensitivity and glucose tolerance.
  • Reduced plasma levels of total cholesterol, triglycerides, LDL-C, HDL-C, and free fatty acids.
  • Decreased expression of IL-6, TNF-alpha, NF-kappaB, and IkappaB kinase-beta, while increasing IkappaB in adipose tissue.

Conclusions:

  • Atorvastatin demonstrates potential for preventing and treating insulin resistance-associated diseases like type 2 diabetes and cardiovascular disease.
  • Amelioration of chronic inflammation is a likely mechanism for atorvastatin's metabolic benefits.
  • Further research supports atorvastatin's role in managing metabolic disorders through anti-inflammatory pathways.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...